GlassScriptPhysician profile
Cheryl A Reed
NPI 1447222914
$5,075.31
in general payments reported to CMS, 2019-2025
48 companies · $920 in 2025
The $920 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,536 · 2020: $128 · 2021: $368 · 2022: $489 · 2023: $661 · 2024: $974 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,554.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $546.92 | 2019-2023 | Spravato |
| Novo Nordisk INC | $538.36 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $417.45 | 2019-2024 | |
| Glaxosmithkline, LLC. | $326.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $281.46 | 2019-2025 | |
| Amgen INC. | $250.28 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $239.21 | 2019-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $178.60 | 2019-2025 | Veozah |
| Lilly USA, LLC | $169.09 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Genentech USA, INC. | $164.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $152.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.51 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $135.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.22 | 2023-2025 | Xifaxan, Ibschek |
| Esperion Therapeutics, INC. | $125.01 | 2021 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $111.86 | 2022 | |
| Intuity Medical INC | $104.29 | 2022 | |
| Inogen, INC. | $97.02 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Exact Sciences Corporation | $92.23 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $89.85 | 2019 | |
| Gilead Sciences, INC. | $70.55 | 2019 | |
| Hologic Sales and Service, LLC | $47.93 | 2023-2024 | Thinprep 2000 Processor, Affirm Prone Biopsy System, Aptima |
| Boston Scientific Corporation | $44.83 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Abbott Laboratories | $42.15 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $42.08 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $40.96 | 2019 | |
| Eisai INC. | $37.19 | 2021 | |
| Scilex Pharmaceuticals INC. | $31.98 | 2019 | |
| Currax Pharmaceuticals LLC | $31.83 | 2024-2025 | Contrave |
| Amarin Pharma, INC. | $29.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.53 | 2019 | |
| Allergan, INC. | $28.52 | 2019 | |
| Seqirus USA INC | $26.46 | 2024 | Flucelvax |
| Noven Therapeutics, LLC | $24.95 | 2025 | Xelstrym |
| Bausch Health US, LLC | $24.17 | 2019 | |
| Corcept Therapeutics | $22.14 | 2025 | Korlym |
| Ibsa Pharma INC. | $22.05 | 2022 | |
| Angiodynamics, INC. | $21.01 | 2020 | |
| Azurity Pharmaceuticals, INC. | $19.89 | 2024 | Horizant |
| Watermark Medical, INC. | $19.17 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.27 | 2023 | Quviviq |
| Shield Therapeutics INC | $15.95 | 2024 | |
| Scpharmaceuticals INC. | $15.58 | 2024 | |
| Ucb, INC. | $14.87 | 2020 | |
| Merck Sharp & Dohme LLC | $14.39 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Biohaven Pharmaceuticals, INC. | $14.34 | 2021 | |
| Lundbeck LLC | $14.02 | 2024 | Rexulti |
| Tanabe Pharma America, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.